Hallusinosis due to methylphenidate overdose in an eight-year-old child: a case report

Ender ATABAY, Ayşe RODOPMAN ARMAN
426 49

Öz


Methylphenidate, which blocks the presynaptic norepinephrine and
dopamine transporters, is the most common used medication and
offered as first choice in the treatment guidelines of attention deficit
hyperactivity disorder (ADHD). One of its rarely seen adverse
effects is, hallucinations that can be formed idiosyncratically,
which can be correlated with increased dopaminergic functioning
in synaptic cleft. We will present an eight year old boy diagnosed
with ADHD-combined type, and oppositional defiant disorder
(ODD) with no previous medical and family history who has
impulsively taken extra dose of methylphenidate in the course of
usual drug treatment. The acute hallucinosis presentation which
has subsided the next day completely with the cessation of drug
treatment will be discussed.
Keywords: Methylphenidate, Hallucinosis, Attention deficit
hyperactive disorder


Tam metin:

PDF (English)


DOI: http://dx.doi.org/10.5472/MMJcr.2903.01

Referanslar


Hodgkins P, Shaw M, Coghill D, et al. Amphetamine

and methylphenidate medications for attention deficit/

hyperactivity disorder: complementary treatment options.

Eur Child Adolesc Psychiatry 2012; 21:477-92. doi: 10.1007/

s00787-012-0286-5

Stahl M S. Stahl’ın Temel Psikofarmakolojisi. 4.Baskı. Alkın

T, çeviri editörü. İstanbul:İstanbul Tıp Kitabevi, 2015; 490-7.

Hesapçıoğlu ST, Göker Z, Bilginer Ç, et al. Methylphenidate

induced psychotic symptoms: two cases report. J Med Cases

; 4:106-8. doi: http://dx.doi.org/10.4021/jmc923w

Carkaxhıu G, Yılmaz S, Sabuncuoğlu O. Stimulant

related psychosis in ADHD treatment: an update for past

years. Curr Psychopharmacol 2013; 2:218-21. doi:

2174/22115560113029990005

Lucas AR, Weiss M. Methylphenidate hallucinosis. JAMA

; 217:1079-81. doi:10.1001/jama.1971.03190080041008

Ross GR. Psychotic and manic-like symptoms during

stimulant treatment of attention deficit hypractivity disorder.

Am J Psychiatry 2006; 163:1149-52. doi:10.1176/appi.

ajp.163.7.1149

Bell V, Raballo A, Laroi F. Assessment of hallucinations.

In: Laroi F, Aleman A, editors. Hallucinations: A Guide to

Treatment and Management. Chapter 19. Oxford:Oxford

University Press, 2010; 389-90.

Abalı O, Mukaddes NM. Metilfenidat tedavisi ile ortaya

çıkan varsanılar: olgu sunumu. Klin Psikofarmakol B 2007;

:195-7.

Rittmannsberger H, Christian F, Holler M. Methylphenidate

for psychosis and aggression in a patient comorbid with

ADHD - A case report. Psychiat Danub 2014; 26:77-9.

Sldhu K, Dickey T. Hallucinations in children: Diagnosis and

treatment strategies. Curr Psychiatry 2010; 9:53-61.

Goetz M, Prıhodova I, Hrdlıcka M. Long lasting complex

nocturnal hallucinations during osmotic release oral system

(OROS) methylphenidat treatment in a 7 year old girl. Neuro

Endocrinol Lett 2011; 32:619-22.

Volkow N, Swanson J. Variables that affect the clinical use

and abuse of methylphenidate in the treatment of ADHD.

Am J Psychiatry 2003; 160:1909-18. doi:http://dx.doi.

org/10.1176/appi.ajp.160.11.1909

Pearson D, Lane D, Santos C, et al. Effects of methylphenidate

treatment in children with mental retardation and ADHD:

individual variation in medication response. J Am Acad

Child Adolesc Psychiatry 2004; 43:686-98. doi:10.1097/01.

chi.0000120024.14101.96

Vles JSH, Feron FJM, Hendriksen JGM, et al.

Methylphenidate down-regulates the dopamine receptor

and transporter system in children with attention deficit

hyperkinetic disorder (ADHD). Neuropediatrics 2003; 34:77-

doi: 10.1055/s-2003-39602

Engert V, Pruessner CJ. Dopaminergic and noradrenergic

contributions to functionality in ADHD: The role of

methylphenidate. Curr Neuropharmacol 2008; 6:322-8.

doi:10.2174/157015908787386069

Bramness JG, Gundersen QH, Guterstam J, et al.

Amphetamine-induced psychosis – a separate diagnostic

entity or primary psychosis triggered in the vulnerable? BMC

Psychiatry 2012; 12:221. doi: 10.1186/1471-244X-12-221

Nevels RM, Weiss NH, Killebrew AE, et al. Methylphenidate

and ıts under-recognised, under-explained and serious drug

interactions: A review of the literature with heightened

concerns. German J Psychiatry 2013; 16:29-42.

Volkow N, Wang GJ, Fowler JS, et al. Relationship between

blockade of dopamine transporters by oral methylphenidat

and the increases in extracellular dopamine: therapeutic

implications. Synapse 2002; 43:181-7. doi:10.1002/

syn.10038

Zhu HJ, Patrick KS, Yuan HJ, et al. Two CES1 gene

mutations lead to dysfunctional carboxylesterase 1 activity in

man: clinical significance and molecular basis. Am J Hum

Genet 2008; 82: 1241-8. doi: 10.1016/j.ajhg.2008.04.015




Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.